Premier Research and BioCentriq Enter a Strategic Partnership to Accelerate Pre-IND Timelines and Clinical Translation of Innovative Cell Therapies
January 9, 2024 – BioManufacturing, Drug Discovery –
8 January 2024 – Morrisville, NC and Newark, NJ, US — Premier Research, a preeminent global clinical research, product development, and consulting company, and BioCentriq, a renowned Contract Development and Manufacturing Organisation (CDMO), have entered a strategic partnership to revolutionise the pre-Investigational New Drug (IND) process and accelerate the clinical translation of novel cell therapy products.
By leveraging Premier Research’s expertise in cell therapy product development and BioCentriq’s proficiency in developing and manufacturing and testing cell therapies, the partnership will streamline the process of bringing new products to patients. As partners, Premier and BioCentriq are well positioned to support sponsors seeking to expedite the transition of their innovative cell therapy candidates from research to clinical trials.
“Partnering with BioCentriq aligns with our commitment to expediting the development of transformative cell therapies,” stated Kenneth Ndugga-Kabuye, MD, FACMG, Vice President, Cell and Gene Therapy at Premier Research. “By merging our comprehensive product development expertise with BioCentriq’s specialised capabilities we will help sponsors simplify the development process from pre-IND through approval, ultimately accelerating the delivery of innovative therapies to patients in need.”
This collaboration will harness Premier Research’s comprehensive understanding of regulatory requirements, clinical trial design and study execution, alongside BioCentriq’s specialised capabilities in cell therapy development.
“Cell therapy development is extremely complex,” added Olu Aloba, PhD, Vice President, Chemical Manufacturing and Control (CMC) Services, Premier Consulting, a business unit of Premier Research, “Nonclinical and Clinical development, CMC, and the CDMO have to work hand in hand to address the scientific, logistical and regulatory demands that enable studies to generate high-quality results.”
“This collaboration marks a significant step in fostering a more streamlined pathway for groundbreaking cell therapies,” remarked Alex Klarer, Vice President, Business Strategy and Innovation at BioCentriq. “Combining Premier Research’s clinical insights with our CDMO expertise will empower us to expedite the translation of novel therapies from the lab to clinical reality, benefiting patients worldwide.”
